文献速递炎症性肠病

生物制剂预防克罗恩病术后内镜复发的真实世界比较效果

Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease.
PubMed 文献 · Am J Gastroenterol · 2026-09-18

基于加拿大卡尔加里健康区2016-2020年231例回结肠切除吻合术的克罗恩病患者回顾性队列,比较生物制剂预防术后内镜复发的效果。高风险复发在未治疗组为42.3%,TNF拮抗剂组9.4%,乌司奴单抗组27.8%,维得利珠单抗组9.5%。加权后所有生物制剂均与内镜复发风险降低相关(aOR 0.15-0.31,均P<0.05)。

要点

  • 生物制剂预防性治疗与克罗恩病术后内镜复发风险降低相关(aOR 0.15-0.31)。
  • 维得利珠单抗复发风险低于乌司奴单抗(aOR 0.24,P=0.04)。
  • 乌司奴单抗和维得利珠单抗均为有效选择,包括既往TNF暴露者。

核心结论

  • 真实世界队列中,生物制剂预防与克罗恩病术后内镜复发风险降低相关。
  • 乌司奴单抗和维得利珠单抗均为有效选择,包括既往TNF暴露者。

研究设计与样本

  • 基于人群的回顾性队列研究,纳入加拿大卡尔加里健康区2016-2020年231例接受回结肠切除吻合术的成人克罗恩病患者。

主要发现

  • 高风险内镜复发(改良Rutgeerts评分≥i2b)在未治疗组为42.3%(36/85),TNF拮抗剂组9.4%(6/64),乌司奴单抗组27.8%(10/36),维得利珠单抗组9.5%(2/21)。
  • 加权后所有生物制剂策略均与内镜复发风险降低相关(aOR 0.15-0.31,均P<0.05)。
  • 维得利珠单抗较乌司奴单抗复发风险更低(aOR 0.24 [0.06-0.92],P=0.04),但与TNF拮抗剂无显著差异(aOR 0.43 [0.10-1.87],P=0.26)。

临床怎么用

  • 对克罗恩病回结肠切除术后患者,可考虑生物制剂预防性治疗以降低内镜复发风险。
  • 维得利珠单抗和乌司奴单抗可作为预防术后复发的有效选择,包括既往TNF暴露者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative recurrence is common after ileocolonic resection for Crohn's disease (CD). Comparative effectiveness data for advanced treatments for preventing recurrence are limited. METHODS: We conducted a population-based retrospective cohort study of adults with CD undergoing ileocolonic resection with primary anastomosis in the Calgary Health Zone, Canada (2016-2020). The primary outcome was endoscopic recurrence within 18 months, assessed using the modified Rutgeerts score as an ordinal endpoint. High-risk recurrence (modified Rutgeerts score ≥ i2b) was evaluated as a secondary outcome. Propensity scores were estimated using established clinical risk factors, and inverse probability of treatment weighting targeting the average treatment effect among treated patients was applied to ordinal and logistic regression models. Treatment effects were expressed as adjusted odds ratios (aOR) with 95% CI. RESULTS: Among 231 patients, 126 (54.5%) received biologic prophylaxis and 92 (39.8%) received no treatment; endoscopy was performed in 217 patients. High-risk endoscopic recurrence occurred in 42.3% (36/85) of untreated patients compared with 9.4% (6/64) receiving tumor necrosis factor (TNF) antagonists, 27.8% (10/36) receiving ustekinumab, and 9.5% (2/21) receiving vedolizumab. After weighting for established risk factors for recurrence, all biologic strategies were associated with reduced odds of endoscopic recurrence compared with no treatment (aOR 0.15-0.31, all P < 0.05). Vedolizumab was associated with lower odds of recurrence compared with ustekinumab (aOR 0.24 [0.06-0.92], P = 0.04) but not TNF antagonists (aOR 0.43 [0.10-1.87], P = 0.26). DISCUSSION: In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ahmed NS, Boparai R, Fida M, et al. Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease. Am J Gastroenterol. 2026. PMID: 42754967. doi:10.14309/ajg.0000000000004213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。